Your browser doesn't support javascript.
loading
Using a Consensus Docking Approach to Predict Adverse Drug Reactions in Combination Drug Therapies for Gulf War Illness.
Jaundoo, Rajeev; Bohmann, Jonathan; Gutierrez, Gloria E; Klimas, Nancy; Broderick, Gordon; Craddock, Travis J A.
Afiliação
  • Jaundoo R; Institute for Neuro-Immune Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA. rj426@nova.edu.
  • Bohmann J; Department of Psychology & Neuroscience, Nova Southeastern University, Fort Lauderdale, FL 33314, USA. rj426@nova.edu.
  • Gutierrez GE; Department of Clinical Immunology, Nova Southeastern University, Fort Lauderdale, FL 33314, USA. rj426@nova.edu.
  • Klimas N; Pharmaceuticals and Bioengineering Department, Southwest Research Institute, San Antonio, TX 78238, USA. jonathan.bohmann@swri.org.
  • Broderick G; Pharmaceuticals and Bioengineering, Chemistry and Chemical Engineering Division, Southwest Research Institute, San Antonio, TX 78238, USA. gloria.gutierrez@swri.org.
  • Craddock TJA; Institute for Neuro-Immune Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA. nklimas@nova.edu.
Int J Mol Sci ; 19(11)2018 Oct 26.
Article em En | MEDLINE | ID: mdl-30373189
Gulf War Illness (GWI) is a chronic multisymptom illness characterized by fatigue, musculoskeletal pain, and gastrointestinal and cognitive dysfunction believed to stem from chemical exposures during the 1990⁻1991 Persian Gulf War. There are currently no treatments; however, previous studies have predicted a putative multi-intervention treatment composed of inhibiting Th1 immune cytokines followed by inhibition of the glucocorticoid receptor (GCR) to treat GWI. These predictions suggest the use of specific monoclonal antibodies or suramin to target interleukin-2 and tumor necrosis factor α , followed by mifepristone to inhibit the GCR. In addition to this putative treatment strategy, there exist a variety of medications that target GWI symptomatology. As pharmaceuticals are promiscuous molecules, binding to multiple sites beyond their intended targets, leading to off-target interactions, it is key to ensure that none of these medications interfere with the proposed treatment avenue. Here, we used the drug docking programs AutoDock 4.2, AutoDock Vina, and Schrödinger's Glide to assess the potential off-target immune and hormone interactions of 43 FDA-approved drugs commonly used to treat GWI symptoms in order to determine their putative polypharmacology and minimize adverse drug effects in a combined pharmaceutical treatment. Several of these FDA-approved drugs were predicted to be novel binders of immune and hormonal targets, suggesting caution for their use in the proposed GWI treatment strategy symptoms.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Síndrome de Fadiga Crônica / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Dor Musculoesquelética / Disfunção Cognitiva / Polifarmacologia / Gastroenteropatias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Síndrome de Fadiga Crônica / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Dor Musculoesquelética / Disfunção Cognitiva / Polifarmacologia / Gastroenteropatias Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2018 Tipo de documento: Article